Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Foster City, California Clinical Trials

A listing of Foster City, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (34) clinical trials

A Pharmacokinetic and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS

The primary objective is to assess the pharmacokinetics (PK) of gabapentin following the single-dose administration of HORIZANT (Gabapentin Enacarbil) in adolescents (13 to 17 years of age) diagnosed with moderate-to-severe Primary Restless Legs Syndrome (RLS).

Phase

5.41 miles

Learn More »

Safety Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF) CLL DLBCL or ATLL

Study Design: Part A: Cohorts of 3-6 patients diagnosed with MF will receive up to five intratumoral injections of MRG-106 over a period of up to 15 days with follow-up for an additional 20 days, beginning with the maximum deliverable intratumoral dose. Doses may be decreased in subsequent cohorts to ...

Phase

6.31 miles

Learn More »

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Phase

9.61 miles

Learn More »

A Study of AK002 in Patients With Atopic Keratoconjunctivitis Vernal Keratoconjunctivitis and Perennial Allergic Conjunctivitis

This is a Phase 1b, open-label, study to assess the effects of AK002, given as monthly intravenous infusion for 6 doses at up to 3 mg/kg.

Phase

9.61 miles

Learn More »

Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

This study is a Phase 1, open-label, dose escalation and cohort expansion trial designed to characterize the safety, tolerability, PK, PD, immunogenicity and preliminary antitumor activity of enoblituzumab administered IV on a weekly schedule for up to 96 doses (approximately 2 years) in children and young adults with B7-H3-expressing relapsed ...

Phase

9.87 miles

Learn More »

Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children

The purpose of this study is to find out what effects, good and/or bad, treatment with a new combination of drugs, cyclophosphamide, etoposide, and carfilzomib has on cancer. In part 1 of the trial, small groups of children will be enrolled in steps. The first group will be given a ...

Phase

9.87 miles

Learn More »

A Safety Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase and an expansion phase.

Phase

9.87 miles

Learn More »

A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy

Prior research suggests that higher vitamin D levels in the blood are associated with reduced brain inflammation among individuals with multiple sclerosis, a disease that is similar to the cerebral demyelinating form of ALD. However, serious side effects (e.g. hypercalcemia, kidney stones) can occur if vitamin D levels get too ...

Phase

9.87 miles

Learn More »

Safety Study of MGD009 in B7-H3-expressing Tumors

This study is a Phase 1 open-label, dose escalation, cohort expansion, and efficacy follow-up study of MGD009 administered intravenously (IV) on an every-other-week schedule for up to one year (14 cycles). The dose escalation phase is designed to characterize the safety and tolerability of MGD009 and to define the maximum ...

Phase

9.87 miles

Learn More »

Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study

Phase 1, open-label, multiple-center study in pediatric patients from 0 to < 18 years of age. Patients will receive a single dose of edoxaban to match either the 30 mg (low dose) or the 60 mg (high dose) exposure in adults. Exact doses will be selected during the study on ...

Phase

9.87 miles

Learn More »